Marlise Rachael Luskin, MD, MSCE, discusses the rationale, structure, and toxicity considerations of pediatric-inspired regimens in AYA ALL.
Marlise Rachael Luskin, MD, MSCE
Advertisement
Articles by Marlise Rachael Luskin, MD, MSCE
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5